Is ESTA a good stock to buy? We came across a bullish thesis on Establishment Labs Holdings Inc. on Valueinvestorsclub.com by greenshoes93. In this article, we will summarize the bulls’ thesis on ESTA. Establishment Labs Holdings Inc.’s share was trading at $70.48 as of March 6th.
Copyright: bbtreesubmission / 123RF Stock Photo
Establishment Labs (ESTA) is a Costa Rican breast implant company that has delivered strong performance in 2025, driven by its innovative Motiva implant platform and expanding market share in the U.S. Motiva’s SmoothSilk technology addresses longstanding challenges in above-the-muscle implant placement by reducing capsular contracture rates to 1–1.5%, compared with competitors in the high single digits, while also shortening recovery times and enhancing procedural outcomes.
Building on this, the company’s next-generation products—Preserve and Mia—further improve patient outcomes by preserving tissue, increasing visible volume by up to 30%, and enabling fast, minimally invasive procedures that can be performed under local anesthesia, significantly expanding the total addressable market. ESTA’s culture emphasizes continuous innovation and physician collaboration, creating a virtuous cycle of product iteration and adoption, with clean-room facilities and quality standards comparable to leading U.S. peers.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains
Operational improvements under new CEO Peter Caldini aim to optimize distributor relationships, particularly outside the U.S., while new partnerships in China could accelerate growth in a key regulatory market. The company benefits from Costa Rica’s Coyol Free Zone tax holiday through 2030, effectively lowering long-term tax rates to approximately 5%, enhancing cash flow as profitability scales.
U.S. market penetration is accelerating, with 40–65% market share potential in augmentation procedures and an upcoming reconstruction market rollout expected to mirror cosmetic market size. Operating leverage continues to improve with higher gross margins and controlled expenses, while scale in U.S. sales drives further efficiency.
Taken together, ESTA’s combination of proprietary product innovation, operational optimization, geographic expansion, and favorable tax positioning supports a forecasted $9 EPS by 2028, implying a $135 stock price at 15x multiple. Key catalysts include continued U.S. share gains, reconstruction market launch, and growth through improved international distributor networks, including China, offering substantial upside with de-risked execution.
Previously, we covered a bullish thesis on Medtronic plc (MDT) by Investing Intel in April 2025, which highlighted its strategic transformation and potential upside from the diabetes spin-off. MDT’s stock has appreciated by 12.66% since our coverage. Greenshoes93 shares a similar view with Establishment Labs Holdings Inc. (ESTA) but emphasizes product innovation, U.S. market share gains, and international expansion.
Establishment Labs Holdings Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 39 hedge fund portfolios held ESTA at the end of the fourth quarter which was 29 in the previous quarter. While we acknowledge the risk and potential of ESTA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ESTA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
